Mental disorders in neurological diseases. Can symptoms of bipolardisorder be the first manifestation of X-linked adenoleukodystrophy?A case report
DOI:
https://doi.org/10.2478/cpp-2020-0011Keywords:
X-linked adrenoleukodystrophy, X-ALD, Lorenzo's oil, bipolar disorder, The Edinburgh Postnatal Depression Scale, depressionAbstract
Background. X-linked adrenoleukodystrophy (X-ALD) is an inherited metabolic disease which causes demyelination of the white matter of the brain. The symptoms include mental impairment, progressive paresis, impaired motor coordination, and epileptic seizures. Diagnosis is established mainly by genetic testing. Currently, the recommended treatment is haematopoietic stem cell transplantation (HSCT).
Aim. The aim of the study was to present the case of a patient suffering from X-ALD, who developed symptoms of bipolar disorder in the initial phase of the disease prior to the onset of characteristic neurological symptoms.
Case presentation. In 2015, a 33-year-old patient was admitted to a psychiatric department due to aggressive behaviour he showed towards his wife and other family members. He had been treated for a depressive episode in 2005, and for a manic episode without psychotic symptoms earlier in 2015. During the successive psychiatric hospitalizations, in addition to psychopathological symptoms, the patient had been observed to have neurological symptoms, which included progressive paraparesis and ataxia. In 2018, based on imaging and genetic tests, the patient was diagnosed with X-ALD. The patient's condition gradually deteriorated; with time, he was unable to move on his own. During a hospital stay in 2019, he was transferred to an internal medicine department due to a progressive urinary tract infection, which, however, could not be controlled, and the patient died.
Conclusions.
1. X-ALD is a rare metabolic illness. In the early stages of the disease, various psychopathological symptoms, including affective disorders, are observed.
2. Early initiation of adequate treatment increases the chances of extending the patient's life.
3. In the present case, the patient did not die due to the underlying disease, but due to causes typical of bed-bound patients, i.e. complications of progressing infection.
References
1. Engelen M., Kemp S., De Visser M., Van Geel B.M., Wanders R.J.A., Aubourg P., et al. X-linked adrenoleukodystrophy (X-ALD): Clinical presentation and guidelines for diagnosis, follow-up and management. Orphanet J Rare Dis. 2012;7: 51.
2. Engelen M., Kemp S., Poll-The B.T. X-linked adrenoleukodystrophy: Pathogenesis and treatment. Current Neurology and Neuroscience Reports. 2014; 14: 486.
3. Liberato A.P., Mallack E.J., Aziz-Bose R., Hayden D., Lauer A., Caruso P.A., et al. MRI brain lesions in asymptomatic boys with X-linked adrenoleukodystrophy. Neurology. 2019; 92: e1698-e1708.
4. Di Rocco M., Doria-Lamba L., Caruso U. Monozygotic twins with X-linked adrenoleukodystrophy and different phenotypes. Ann Neurol. 200; 50: 424.
5. Siva Ilango T., Nambi S. X-linked adrenoleukodystrophy presenting as attention deficit hyperactivity disorder. Indian J Psychiatry. 2015; 57: 208-209.
6. David R.B. Clinical pediatric neurology. Demos Medical; 2009.
7. Smith J., Williams M.T., Misra V.K. Psychiatric disease in an adolescent as a harbinger of cerebral X-linked adrenoleukodystrophy. Pract Neurol. 2018; 18: 242–245.
8. Jyothi K., George C., Shaji K. A case of adrenoleukodystrophy presenting with manic symptoms in a patient on steroids for Addison’s disease. Indian J Psychiatry. 2016; 58: 467–470.
9. Chen Y.H., Lee Y.C., Tsai Y.S., Guo Y.C., Hsiao C.T., Tsai P.C., et al. Unmasking adrenoleukodystrophy in a cohort of cerebellar ataxia. PLoS One. 2017; 12: e0177296.
10. Shamim D., Alleyne K. X-linked adult-onset adrenoleukodystrophy: Psychiatric and neurological manifestations. SAGE Open Med Case Reports. 2017; 5:2050313X1774100.
11. Ray A., Girimaji S.C., Bharath R.D. Adolescent-onset X-linked adrenoleukodystrophy presenting as treatment-resistant bipolar disorder. Indian J Psychol Med. 2017; 39: 685-687.
12. Traboulsi E.I., Maumenee I.H. Ophthalmologic Manifestations of X-linked Childhood Adrenoleulcodystrophy. Ophthalmology. 1987; 94: 47-52.
13. Van Geel B.M., Assies J., Wanders R.J.A., Barth P.G. X linked adrenoleukodystrophy: Clinical presentation, diagnosis, and therapy. J Neurol Neurosurg Psychiatry. 1997; 63: 4-14.
14. Lourenço C.M., Simão G.N., Santos A.C., Marques W. Adrenoleucodistrofa ligada ao X em pacientes femininas heterozigotas: Mulheres não são meras portadoras. Arq. Neuro-Psiquiatr. 2012, 70: 487-491.
15. Rowland L.P., Kamińska A., Domitrz I., Kwieciński H. Neurologia Merritta. Wydawnistwo Medyczne Urban & Partner; 2004. 996 p.
16. Bekesińska-Figatowska M., Walecki J., Wagiel K. Wartość rezonansu magnetycznego w diagnostyce wrodzonych chorób istoty białej innych zwyrodnieniowych chorób ośrodkowego układu nerwowego. Neurol Neurochir Pol. 2001; 35: 605–619.
17. Bekesińska-Figatowska M., Jurkiewicz E., Wagiel K., Kmieć T. Miejsce rezonansu magnetycznego włańcuchu diagnostycznym wrodzonych chorób istoty białej i innych zwyrodnieniowych chorób ośrodkowego układu nerwowego u dzieci. Neurol Dziec. 2005; 14:37-45.
18. Moser A.B., Moser H.W. The Prenatal Diagnosis of X-linked Adrenoleukodystrophy. Prenatal Diagnosis. 1999; 19: 46-48.
19. Morski J. X linked adrenoleukodystrophy. Clinical presentation, diagnosis, therapy and case report. Neurologia Dziecięca. 2012; 43: 47-54.
20. Lerner B.H. Complicated lessons: Lorenzo Odone and medical miracles. Lancet. 2009; 373: 888–889.
21. Moser H.W., Raymond G.V., Lu S.E., Muenz L.R., Moser A.B., Xu J., et al. Follow-up of 89 asymptomatic patients with adrenoleukodystrophy treated with Lorenzo’s oil. Arch Neurol. 2005; 62: 1073-1080.
22. Chai B.C., Etches W.S., Stewart M.W., Siminoski K. Short reports Bleeding in a patient taking Lorenzo’s oil: evidence for a vascular defect. Postgrad Med J7 1996; 72: 113-122.
23. Kemp S., Huffnagel I.C., Linthorst G.E., Wanders R.J., Engelen M. Adrenoleukodystrophy - Neuroendocrine pathogenesis and redefinition of natural history. Nat Rev Endocrinol. 2016; 12: 606-615.
24. Turk B.R., Theda C., Fatemi A., Moser A.B. X-linked Adrenoleukodystrophy: Pathology, Pathophysiology, Diagnostic Testing, Newborn Screening, and Therapies. Int J Dev Neurosci. 2020; 80: 52-72.
25. Engelen M., Schackmann M.J.A., Ofman R., Sanders R.J., Dijkstra I.M.E., Houten S.M., et al. Bezafibrate lowers very long-chain fatty acids in X-linked adrenoleukodystrophy fibroblasts by inhibiting fatty acid elongation. J Inherit Metab Dis. 2012; 35:1137–1145.
26. Schackmann M.J.A. Biochemical and cell biological aspects of X-linked adrenoleukodystrophy. 23 May 2017 (Doctoral Thesis). 27. Nascimento M., Rodrigues N., Espada F., Fonseca M.
27. Adrenoleukodystrophy: A forgotten diagnosis in children with primary Addison’ s disease. BMJ Case Reports 2012; doi:10.1136/bcr-2012-006308
28. Berger J., Forss-Petter S., Eichler F.S. Pathophysiology of X-linked adrenoleukodystrophy. Biochimie. 2014; 98:135-142.
29. Berger J., Pujol A., Aubourg P., Forss-Petter S. Current and future pharmacological treatment strategies in X-linked adrenoleukodystrophy. Brain Pathol. 2010; 20: 845-856.
30. Cartier N., Aubourg P. Hematopoietic stem cell transplantation and hematopoietic stem cell gene therapy in X-linked adrenoleukodystrophy. Brain Pathol. 2010; 20: 857-862.
31. Fichna M., Fichna P., Korman E. Adrenoleukodystrophypathogenesis, diagnosis and therapy, Pediatric Endocrinology. 2004; 1: 57-67.
Downloads
Published
Issue
Section
License
Copyright (c) 2020 Authors
This work is licensed under a Creative Commons Attribution 4.0 International License.
